Open AccessEarly Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
Author(s) -
Jihye Park,
Jae Hee Cheon,
KangMoon Lee,
Young-Ho Kim,
Byong Duk Ye,
Chang Soo Eun,
Sung Hyun Kim,
Sun Hee Lee,
Joon Ho Lee,
Stefan G. Schreiber
Publication year - 2022
Publication title -
gut and liver
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.331
H-Index - 44
eISSN - 2005-1212
pISSN - 1976-2283
DOI - 10.5009/gnl220005
Subject(s) - infliximab , medicine , crohn's disease , biosimilar , trough (economics) , randomized controlled trial , term (time) , disease , gastroenterology , physics , quantum mechanics , economics , macroeconomics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom